VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
TLRY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
TLRYTilray Brands, Inc.
$4.38$510M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

TLRY logoTilray Brands, Inc.(TLRY)Earnings, Financials & Key Ratios

TLRY•NASDAQ
$4.38
Price updated Jul 6, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryCannabis and cannabinoid product companies
AboutTilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.Show more
  • Revenue$1.13B+4.8%
  • EBITDA-$2.95B-4425.0%
  • Net Income-$3B-798.9%
  • EPS (Diluted)-33.80-651.7%
  • Gross Margin29.29%+3.5%
  • EBITDA Margin-261.68%-4216.2%
  • Operating Margin-277.94%-1154.8%
  • Net Margin-266.25%-757.4%
  • ROE-89.1%-1124.7%

TLRY Price & Volume

Tilray Brands, Inc. (TLRY) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operating Losses Obscure Strategic Realignment

Investment Thesis • Updated 2026Q2

VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Strained
Cash Flow:Burning
Primary Risk:Persistent Operating Margin Deficits

Key Thesis Takeaways

  • Tilray Brands faces a complex structural challenge as it attempts to integrate diverse business segments while struggling with persistent operating losses and a $6.8B accumulated deficit in retained earnings.
  • While management has successfully reduced total debt from $762.2M in 2024Q1 to $446.5M in 2026Q2, the company remains trapped in a cycle of low-margin pharmaceutical distribution and capital-intensive operations.
  • Investors should remain cautious as the firm's inability to achieve consistent positive free cash flow, evidenced by a $25.5M outflow in 2026Q2, suggests that the current diversified conglomerate model may continue to erode shareholder value.

Verdict Logic

the company's inability to generate positive free cash flow, evidenced by a $25.5M outflow in 2026Q2, combined with a $6.8B accumulated deficit, indicates that the current business model is not yet self-sustaining.

TLRY Growth Metrics

Tilray Brands, Inc. (TLRY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years119.02%
5 Years22.69%
3 Years12.47%
TTM3.03%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-764.38%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-649.35%

Return on Capital

10 Years-27.93%
5 Years-26.22%
3 Years-37.88%
Last Year-78.12%

TLRY Recent Earnings

Tilray Brands, Inc. (TLRY) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Apr 1, 2026
Metric
Actual
Est
EPS
$0.24-71.4%
$0.14
Rev
$207M+2.7%
$201M
Q1 2026
Jan 8, 2026
Metric
Actual
Est
EPS
$0.41-192.9%
$0.14
Rev
$218M+3.1%
$211M
Q4 2025
Oct 9, 2025
Metric
Actual
Est
EPS
$0.00+98.4%
$0.27
Rev
$288M+40.7%
$205M
Q3 2025
Jul 28, 2025
Metric
Actual
Est
EPS
$0.02+166.7%
$0.03
Rev
$224M+7.7%
$208M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 1, 2026
$0.24vs $0.14-71.4%
$207Mvs $201M+2.7%
Q1 2026Jan 8, 2026
$0.41vs $0.14-192.9%
$218Mvs $211M+3.1%
Q4 2025Oct 9, 2025
$0.00vs $0.27+98.4%
$288Mvs $205M+40.7%
Q3 2025Jul 28, 2025
$0.02vs $0.03+166.7%
$224Mvs $208M+7.7%
Based on last 12 quarters of dataView full earnings history →

Latest TLRY News

Recent stock market news and headlines for Tilray Brands, Inc. (TLRY)

MarijuanaStocks·1 day ago
Top Canadian Marijuana Stock Picks For Investors Today

As the cannabis sector continues to grow, it has marijuana stock investors seeing green. There has been a long, volatile battle for most of the time cannabis companies have been publicly traded. Even during the moments when many used pot stocks to get quick profits, given how the sector once began. At one point, a great deal of hype and speculation fueled investors in taking up positions for particular cannabis stocks.

The Motley Fool·4 days ago
Is Tilray a Textbook Value Trap -- or the Most Undervalued Cannabis Stock on the Market?

Tilray hopes that several ongoing developments will help it rebound. But the company's outlook remains highly uncertain.

Zacks Investment Research·5 days ago
TLRY Plans Strategic Medical Cannabis Expansion: Time to Buy or Sell?

Tilray expands its medical cannabis strategy with HelloMD, adding virtual patient access as investors weigh growth potential against ongoing profitability challenges.

24/7 Wall Street·5 days ago
A Revolutionary Technology Narrative Has Surged—Don't Take the Bait

Although the growth rates coming out of the quantum computing segment look genuinely spectacular on paper, Wall Street has stood on this exact ledge before, and the fall has never been gentle.

Zacks Investment Research·5 days ago
Tilray Brands, Inc. (TLRY) Suffers a Larger Drop Than the General Market: Key Insights

The latest trading day saw Tilray Brands, Inc. (TLRY) settling at $4.43, representing a -1.34% change from its previous close.

Peers Comparison

Key metrics vs top competitors for Tilray Brands, Inc. (TLRY)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
TLRY logoTLRYTilray Brands, Inc.Current
$4.38$510.37M-0.134.84%-266.25%-89.1%—
CGC logoCGCCanopy Growth Corporation
$0.96$369.59M-1.555.8%-91.63%-38.64%—
CRON logoCRONCronos Group Inc.
$2.76$1.03B-112.6564.4%-0.98%-0.18%—
ACB logoACBAurora Cannabis Inc.
$2.71$167.86M-1.79-6.37%-24.14%-13.4%—
SMG logoSMGThe Scotts Miracle-Gro Company
$67.08$3.9B27.16-3.93%3.27%——
IIPR logoIIPRInnovative Industrial Properties, Inc.
$61.86$1.77B15.74-13.8%45.58%6.41%—

Compare TLRY vs Peers

Tilray Brands, Inc. (TLRY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CGC

Most directly comparable listed peer for TLRY.

Scale Benchmark

vs BUD

Larger-name benchmark to compare TLRY against a more recognizable public peer.

Peer Set

Compare Top 5

vs CGC, CRON, ACB, SMG

TLRY SEC Filings & Documents

Tilray Brands, Inc. (TLRY) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 15, 2026·SEC

Material company update

Apr 15, 2026·SEC

Material company update

Apr 1, 2026·SEC

10-K Annual Reports

2
FY 2025

Jul 29, 2025·SEC

FY 2024

Jul 30, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Apr 1, 2026·SEC

FY 2026

Jan 8, 2026·SEC

FY 2025

Oct 9, 2025·SEC

Get notified when TLRY posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

TLRY Frequently Asked Questions

Tilray Brands, Inc. (TLRY) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Tilray Brands, Inc.'s revenue?

Tilray Brands, Inc. (TLRY) reported $1.17B in revenue for fiscal year 2025.

How fast is Tilray Brands, Inc. growing?

Tilray Brands, Inc. (TLRY) grew revenue by 4.8% over the past year. Growth has been modest.

Is TLRY profitable?

Tilray Brands, Inc. (TLRY) reported a net loss of $2.95B for fiscal year 2025.

Dividend & Returns
What is TLRY's return on equity?

Tilray Brands, Inc. (TLRY) has a return on equity (ROE) of -89.1%. Negative ROE indicates the company is unprofitable.

What is Tilray Brands, Inc.'s free cash flow?

Tilray Brands, Inc. (TLRY) had negative free cash flow of $94.5M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in TLRY back in 2012?

Total return calculator · dividends reinvested · 14+ years of data

See returns →